What is Eli Lilly's Zepbound? FDA approves new weight loss drug
The FDA has approved a type 2 diabetes drug for chronic weight management.
Tirzepatide is already widely prescribed off-label for weight loss. FDA has just made it official for use.
The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss.
Created by Eli Lilly, it is part of a new class of drugs, including semaglutide, known for weight loss.
In clinical trials, Zepbound yielded over 20% average weight loss on higher doses over 72 weeks.
Its side effects are gastrointestinal issues like nausea, vomiting, constipation, and diarrhea.
Zepbound will cost about $1,060 per month before insurance, the company said.
Patients with commercial insurance can buy the drug for $25 for one or three-month prescription.
Stay updated on all the latest tips, tricks, and trends in health and wellness with Beem.
See More Stories